Until recently, the only available means for risk-stratifying men with clinically localized prostate cancer (PCa) was through the use of clinicopathologic variables such as prostate-specific antigen (PSA) level, histologic grade group, and clinical stage (1, 2). This evidence concerns the gene KLK3 and posterior cortical atrophy.